Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chinese Patent Office
Deloitte
Cerilliant
Julphar
Boehringer Ingelheim
Accenture
Mallinckrodt
Daiichi Sankyo

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DROSPIRENONE; ESTRADIOL

« Back to Dashboard

Clinical Trials for Drospirenone; Estradiol

Trial ID Title Status Sponsor Phase Summary
NCT00102141 Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women Completed Bayer Phase 3 The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.
NCT00356447 Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. Completed Bayer Phase 3 The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.
NCT00413062 Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722) Completed Merck Sharp & Dohme Corp. Phase 3 The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.
NCT00420342 Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension Completed Bayer Phase 2 The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
NCT00446199 Low-dose Hormone Therapy for Relief of Vasomotor Symptoms Completed Bayer Phase 3 The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
NCT00511199 Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724) Completed Merck Sharp & Dohme Corp. Phase 3 The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.
NCT00511433 Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723) Completed Merck Sharp & Dohme Corp. Phase 3 The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Drospirenone; Estradiol

Condition Name

Condition Name for Drospirenone; Estradiol
Intervention Trials
Contraception 11
Polycystic Ovary Syndrome 4
Premenstrual Syndrome 4
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Drospirenone; Estradiol
Intervention Trials
Syndrome 6
Premenstrual Syndrome 4
Polycystic Ovary Syndrome 4
Dysmenorrhea 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Drospirenone; Estradiol

Trials by Country

Trials by Country for Drospirenone; Estradiol
Location Trials
United States 135
China 23
Germany 23
Austria 9
United Kingdom 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Drospirenone; Estradiol
Location Trials
Pennsylvania 8
Florida 7
California 7
Arizona 6
Massachusetts 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Drospirenone; Estradiol

Clinical Trial Phase

Clinical Trial Phase for Drospirenone; Estradiol
Clinical Trial Phase Trials
Phase 4 9
Phase 3 21
Phase 2 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Drospirenone; Estradiol
Clinical Trial Phase Trials
Completed 30
Recruiting 4
Unknown status 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Drospirenone; Estradiol

Sponsor Name

Sponsor Name for Drospirenone; Estradiol
Sponsor Trials
Bayer 21
Massachusetts General Hospital 3
Merck Sharp & Dohme Corp. 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Drospirenone; Estradiol
Sponsor Trials
Industry 31
Other 19
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fish and Richardson
AstraZeneca
Teva
Cipla
Deloitte
Accenture
Healthtrust
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.